Annual CFF
$6.64 M
+$4.65 M+234.08%
December 31, 2023
Summary
- As of February 7, 2025, SLRX annual cash flow from financing activities is $6.64 million, with the most recent change of +$4.65 million (+234.08%) on December 31, 2023.
- During the last 3 years, SLRX annual CFF has fallen by -$11.05 million (-62.47%).
- SLRX annual CFF is now -91.79% below its all-time high of $80.84 million, reached on December 31, 2015.
Performance
SLRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$1.37 M
+$1.40 M+4950.71%
September 30, 2024
Summary
- As of February 7, 2025, SLRX quarterly cash flow from financing activities is $1.37 million, with the most recent change of +$1.40 million (+4950.71%) on September 30, 2024.
- Over the past year, SLRX quarterly CFF has increased by +$1.54 million (+892.07%).
- SLRX quarterly CFF is now -98.31% below its all-time high of $80.84 million, reached on March 31, 2015.
Performance
SLRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$997.60 K
+$1.58 M+271.38%
September 30, 2024
Summary
- As of February 7, 2025, SLRX TTM cash flow from financing activities is $997.60 thousand, with the most recent change of +$1.58 million (+271.38%) on September 30, 2024.
- Over the past year, SLRX TTM CFF has dropped by -$5.13 million (-83.73%).
- SLRX TTM CFF is now -98.77% below its all-time high of $80.84 million, reached on December 31, 2015.
Performance
SLRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SLRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +234.1% | +892.1% | -83.7% |
| 3 y3 years | -62.5% | -79.5% | -85.6% |
| 5 y5 years | +5526.8% | -79.5% | -85.6% |
SLRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -76.5% | +234.1% | -79.5% | +745.9% | -96.5% | +271.4% |
| 5 y | 5-year | -76.5% | +234.1% | -95.2% | +482.0% | -97.3% | +271.4% |
| alltime | all time | -91.8% | >+9999.0% | -98.3% | +482.0% | -98.8% | +271.4% |
Salarius Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.37 M(-4950.7%) | $997.60 K(-271.4%) |
| Jun 2024 | - | -$28.20 K(-83.7%) | -$582.10 K(-109.5%) |
| Mar 2024 | - | -$172.70 K(+1.9%) | $6.13 M(-7.7%) |
| Dec 2023 | $6.64 M(+234.1%) | -$169.40 K(-20.0%) | $6.64 M(-2.5%) |
| Sep 2023 | - | -$211.80 K(-103.2%) | $6.81 M(-1.8%) |
| Jun 2023 | - | $6.68 M(+1885.2%) | $6.94 M(+198.4%) |
| Mar 2023 | - | $336.70 K(>+9900.0%) | $2.32 M(+16.9%) |
| Dec 2022 | $1.99 M(-93.0%) | $0.00(-100.0%) | $1.99 M(-1.6%) |
| Sep 2022 | - | -$85.70 K(-104.1%) | $2.02 M(-19.6%) |
| Jun 2022 | - | $2.07 M(>+9900.0%) | $2.51 M(+3054.3%) |
| Mar 2022 | - | $0.00(-100.0%) | $79.60 K(-99.7%) |
| Dec 2021 | $28.30 M(+59.9%) | $31.30 K(-92.3%) | $28.30 M(-9.3%) |
| Sep 2021 | - | $406.40 K(-213.5%) | $31.20 M(-13.0%) |
| Jun 2021 | - | -$358.10 K(-101.3%) | $35.88 M(-1.1%) |
| Mar 2021 | - | $28.22 M(+860.8%) | $36.29 M(+105.1%) |
| Dec 2020 | $17.69 M(+394.3%) | $2.94 M(-42.3%) | $17.69 M(+3.3%) |
| Sep 2020 | - | $5.09 M(+9573.2%) | $17.13 M(+44.7%) |
| Jun 2020 | - | $52.60 K(-99.5%) | $11.84 M(-10.3%) |
| Mar 2020 | - | $9.62 M(+304.8%) | $13.20 M(+268.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $3.58 M(+2933.3%) | $2.38 M(-1259.5%) | $3.58 M(+197.4%) |
| Sep 2019 | - | -$204.90 K(-114.5%) | $1.20 M(-14.5%) |
| Jun 2019 | - | $1.41 M(>+9900.0%) | $1.41 M(+2132.0%) |
| Mar 2019 | - | $0.00(0.0%) | $63.10 K(-46.5%) |
| Dec 2018 | $118.00 K(+4438.5%) | $0.00(0.0%) | $118.00 K(-0.5%) |
| Sep 2018 | - | $0.00(-100.0%) | $118.60 K(0.0%) |
| Jun 2018 | - | $63.10 K(+14.9%) | $118.60 K(+106.3%) |
| Mar 2018 | - | $54.90 K(+9050.0%) | $57.50 K(+2111.5%) |
| Dec 2017 | $2600.00(-88.2%) | $600.00(>+9900.0%) | $2600.00(+30.0%) |
| Sep 2017 | - | $0.00(-100.0%) | $2000.00(-87.6%) |
| Jun 2017 | - | $2000.00(>+9900.0%) | $16.10 K(+11.0%) |
| Mar 2017 | - | $0.00(0.0%) | $14.50 K(-34.4%) |
| Dec 2016 | $22.10 K(-100.0%) | $0.00(-100.0%) | $22.10 K(-7.9%) |
| Sep 2016 | - | $14.10 K(+3425.0%) | $24.00 K(+80.5%) |
| Jun 2016 | - | $400.00(-94.7%) | $13.30 K(-16.4%) |
| Mar 2016 | - | $7600.00(+300.0%) | $15.90 K(-100.0%) |
| Dec 2015 | $80.84 M | $1900.00(-44.1%) | $80.84 M(+0.0%) |
| Sep 2015 | - | $3400.00(+13.3%) | $80.84 M(+0.0%) |
| Jun 2015 | - | $3000.00(-100.0%) | $80.84 M(+0.0%) |
| Mar 2015 | - | $80.84 M | $80.84 M |
FAQ
- What is Salarius Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Salarius Pharmaceuticals?
- What is Salarius Pharmaceuticals annual CFF year-on-year change?
- What is Salarius Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Salarius Pharmaceuticals?
- What is Salarius Pharmaceuticals quarterly CFF year-on-year change?
- What is Salarius Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Salarius Pharmaceuticals?
- What is Salarius Pharmaceuticals TTM CFF year-on-year change?
What is Salarius Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of SLRX is $6.64 M
What is the all time high annual CFF for Salarius Pharmaceuticals?
Salarius Pharmaceuticals all-time high annual cash flow from financing activities is $80.84 M
What is Salarius Pharmaceuticals annual CFF year-on-year change?
Over the past year, SLRX annual cash flow from financing activities has changed by +$4.65 M (+234.08%)
What is Salarius Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of SLRX is $1.37 M
What is the all time high quarterly CFF for Salarius Pharmaceuticals?
Salarius Pharmaceuticals all-time high quarterly cash flow from financing activities is $80.84 M
What is Salarius Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, SLRX quarterly cash flow from financing activities has changed by +$1.54 M (+892.07%)
What is Salarius Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of SLRX is $997.60 K
What is the all time high TTM CFF for Salarius Pharmaceuticals?
Salarius Pharmaceuticals all-time high TTM cash flow from financing activities is $80.84 M
What is Salarius Pharmaceuticals TTM CFF year-on-year change?
Over the past year, SLRX TTM cash flow from financing activities has changed by -$5.13 M (-83.73%)